Trials / Completed
CompletedNCT03629951
A Study for Schizophrenia Relapse Prediction
An Observational Study for Schizophrenia Relapse Prediction
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 333 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of pre-relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Antipsychotics (OAP) | This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician. |
Timeline
- Start date
- 2018-11-29
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2018-08-14
- Last updated
- 2025-04-27
Locations
10 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03629951. Inclusion in this directory is not an endorsement.